Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

10

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Retinoic acid receptor

6

Retinoic acid receptor beta

6

Retinoic acid receptor gamma

6

Retinoid X receptor alpha

6

Retinoid X receptor gamma

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

10

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1947

4

1971

6

2009

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

6

Acne vulgaris

6

Acute promyelocytic leukemia

6

severe recalcitrant nodular acne

6

Maternal morbidity

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

11

Palliative

10

Preventing

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

6

CNS Penetrant

4

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ligand Pharmaceuticals

6

University of Wisconsin-Madison

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

11

EPA CompTox

11

FDA UNII

11

PUBCHEM

10

NCI_THESAURUS

9

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

4

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

ALIMENTARY TRACT AND METABOLISM

1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-ACNE PREPARATIONS

3

ANTINEOPLASTIC AGENTS

2

DIAGNOSTIC AGENTS

1

NASAL PREPARATIONS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

3

OTHER ANTINEOPLASTIC AGENTS

2

ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

1

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

1

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Retinoids for topical use in acne

3

Other antineoplastic agents

2

Agents for dermatitis, excluding corticosteroids

1

Other dermatologicals

1

Other nasal preparations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

8

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

Tretinoin

5688UTC01R

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

CURCUMIN

IT942ZTH98

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2009

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Vitamin D3 receptor

Conditions:

Prostate cancer

Curcumin is a bright yellow chemical produced by some plants, for example, it is the principal curcuminoid of turmeric. It is sold as a food flavoring, food colorant, herbal supplement, and cosmetic ingredient. Although curcumin has been widely studi...

ed it has not been officially endorsed for any pharmaceutical use due to issues of stability and bioavailability; although it continues to b marketed as a health supplement. Curcumin has been investigated for the treatment of a number of cancers, asthma, mucositis, schizophrenia, mild cognitive impairment, and depression.

VITAMIN A

81G40H8B0T

Status:

US Approved Rx (2001)

First approved in 1947

Class:

MIXTURE

Targets:

Superoxide dismutase

Lecithin retinol acyltransferase

11-cis retinol dehydrogenase

Retinol dehydrogenase 12

Conditions:

Vitamin A deficiency

Maternal morbidity

Maternal mortality

Vitamin A deficiency

Skin photodamage

Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic ...

precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage.

Alitretinoin

1UA8E65KDZ

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

TRETINOIN ZINC

7A9179CU3G

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

SODIUM RETINOATE

DD7YX785YA

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

ISOTRETINOIN ANISATIL

922SI67369

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

Isotretinoin

EH28UP18IF

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

RETINOL

G2SH0XKK91

Export Data
Search for Structure

Status:

US Approved Rx (2001)

First approved in 1947

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Superoxide dismutase

Lecithin retinol acyltransferase

11-cis retinol dehydrogenase

Retinol dehydrogenase 12

Conditions:

Vitamin A deficiency

Maternal morbidity

Maternal mortality

Vitamin A deficiency

Skin photodamage

Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic ...

precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage.

VITAMIN A ACETATE

3LE3D9D6OY

Export Data
Search for Structure

Status:

US Approved Rx (2001)

First approved in 1947

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Superoxide dismutase

Lecithin retinol acyltransferase

11-cis retinol dehydrogenase

Retinol dehydrogenase 12

Conditions:

Vitamin A deficiency

Maternal morbidity

Maternal mortality

Vitamin A deficiency

Skin photodamage

Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic ...

precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage.

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1